Tag: Vaccine Production

The Russian government will fund the reconstruction of Microgen

microgen
The Russian government decided to provide a subsidy from the federal budget to NPO Microgen for the reconstruction and technical re-equipment of its production facilities for influenza vaccines in 2018-2021.

Kirov pharma cluster participants explored biotech development in France

kirov-france
The delegation of the government of the Kirov region visited the Lyonbiopôle in France, which is largest pharmaceutical cluster in the world.

FORT increases its sales of influenza vaccine

fort
In 2018, FORT, a biopharmaceutical company which is part of Marathon Group and Nacimbio (Rostec Corporation), doubled its yoy sales of Ultrex, an influenza vaccine.

Nacimbio supplied more than 1 million doses of TBE vaccine

microgen
In January - May 2018, Nacimbio, a pharmaceutical holding company of Rostec Corporation, has supplied to all regions of Russia more than 1 million doses of vaccines for prevention of tick-borne encephalitis (TBE).

Russia will have its first quadrivalent influenza vaccine

petrovax
According to the experts, this vaccine has not only the most effective and safe profile possible today, but also provides undeniable pharmacoeconomic advantages.

Today’s realities in the development of local and contract manufacturing

forum
The representatives of pharmaceutical companies met at the forum of the Adam Smith Institute where they shared their views on the development of local and contract manufacturing.

Microgen increased its medicines output by 16%

microgen
NPO Microgen, a subsidiary of Nacimbio (part of Rostec Corporation), published its results for 2017. The company's revenue reached 7.7 billion rubles.

Nacimbio was designated as vaccines supplier for National Vaccination Schedule

nacimbio
Nacimbio JSC, a pharmaceutical holding company of Rostec Corporation, received the status of sole supplier of immunobiological medicines used for vaccinations under the National Vaccination Schedule.

Sanofi will pump €350 million into construction of its new Canadian facility

sanofi
Sanofi, a leading global pharmaceutical company, is investing €350 million for the construction of a new state-of-the-art vaccine manufacturing facility at the Sanofi Pasteur Canadian headquarters in Toronto, Ontario.

A memorandum signed to promote Russian products onto the Chilean market

chile-russia
The representatives of the Public Health Institute of Chile visited a vaccine production facility of St. Petersburg Institute of Vaccines and Serums in order to continue and expand cooperation between Russia and Chile.

3P Biopharmaceuticals signed a contract manufacturing agreement with Intervacc

vaccine
3P Biopharmaceuticals, a Spanish biotechnology company, and the Swedish company Intervacc completed negotiations and signed the agreement for contract manufacturing of Strangvac®.

In 2017 Nanolek demonstrates the first results of its active market development

nanolek
In 2017, the revenue of Nanolek LLC reached 2.6 billion rubles, which is a 3-fold increase compared to 2016. The output of medicinal products at the Nanolek plant in the Kirov region amounted to 8.1 million packages.

Vnesheconombank restructures the debt of Ryazan-based FORT

fort
Vnesheconombank allowed FORT, a pharmaceutical manufacturer based in Ryazan, to continue using its credit facility on the terms favorable for the company

Anton Katlinsky says that Russia cannot wait in a queue to get the vaccines

katlinskiy
Anton Katlinsky, the Advisor to the CEO of Nacimbio and the President of FORT, a biopharmaceutical company, discussed with other experts the scenarios for provision of vaccines to the Russian market

Panacea Biotech signs an important deal with Serum Institute of India

vaccine
Panacea Biotech Ltd., India's leading biopharmaceutical company and the largest manufacturer of vaccines, has signed two long-term collaboration agreements with Serum Institute of India

MSD considers the possibility of localizing the vaccines manufacturing in Russia

research
According to Marwan Akar, MSD Director General in Russia, Kazakhstan and Belarus, the company is exploring the possibility of localizing in Russia the manufacturing of vaccines